Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.20Aarti Drugs Ltd. presents a mixed financial picture. The company demonstrates exceptional strength in its long-term financial stability, profitability, and growth prospects. It has very low debt, indicating a conservative and safe financial structure. Furthermore, it is highly profitable, effectively turning revenue into profit and showing strong growth in sales and earnings. However, the company faces significant challenges in its day-to-day operations. Its ability to meet short-term financial obligations is strained, and it is inefficient in using its assets to generate sales. It takes a long time to sell its inventory and collect payments from customers, which can impact cash flow. The outlook suggests a profitable and growing company, but one whose operational inefficiencies are a notable risk.
Health Score : 7.20Aarti Drugs Ltd. presents a mixed financial picture. The company demonstrates exceptional strength in its long-term financial stability, profitability, and growth prospects. It has very low debt, indicating a conservative and safe financial structure. Furthermore, it is highly profitable, effectively turning revenue into profit and showing strong growth in sales and earnings. However, the company faces significant challenges in its day-to-day operations. Its ability to meet short-term financial obligations is strained, and it is inefficient in using its assets to generate sales. It takes a long time to sell its inventory and collect payments from customers, which can impact cash flow. The outlook suggests a profitable and growing company, but one whose operational inefficiencies are a notable risk.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
23.04
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
20.00
P/B RATIO
2.51
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.64
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-2.86
EV/EBITDA RATIO
14.31
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹427.1 as on Sep 1, 2026.
Growth Score : 9.40The company demonstrates an excellent growth trajectory. It has shown a strong ability to increase its revenue, profits, and overall asset base over time. This indicates robust market demand for its products or services and successful business expansion strategies. The growth in earnings per share is particularly strong, suggesting that this expansion is creating significant value for shareholders. This impressive growth profile is a key strength for the company's future outlook.
Revenue Growth RateExcellentOperating Profit Growth RateAverageEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 15.5 | 9.12 | -6.89 | -5.61 | 7.46 |
| Operating Profit Growth Rate | -24.32 | -7.21 | 3.88 | -9.66 | 6.55 |
| Earnings Per Share (EPS) Growth | -26.42 | -18.88 | 3.84 | -1.23 | 15.96 |
| Asset Growth Rate | 25.03 | 9.65 | 0.45 | 5.88 | 9.32 |
| Net Income Growth Rate | -26.79 | -19.02 | 3.61 | -2.33 | 16.07 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 6 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 12 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 13 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 14 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 15 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 16 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 17 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 19 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤3rd Feb 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Aarti Drugs Ltd. is a prominent Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, and Specialty Chemicals. It caters to a diverse range of therapeutic areas, serving both domestic and international markets with a focus on cost-effective and quality products for various ailments.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Aarti Drugs Ltd's P/E ratio (TTM) is 23.04, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Aarti Drugs Ltd's P/B ratio is 2.51, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Aarti Drugs Ltd's P/S ratio is 1.64, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Aarti Drugs Ltd's PEG ratio is -2.86.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Aarti Drugs Ltd's EV/EBITDA ratio is 14.31.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Aarti Drugs Ltd's ROE is 12.59%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Aarti Drugs Ltd's ROA is 10.98%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Aarti Drugs Ltd's ROCE is 12%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Aarti Drugs Ltd's operating margin is 12.05%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Aarti Drugs Ltd's net margin is 7.60%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Aarti Drugs Ltd's current ratio is 1.48.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Aarti Drugs Ltd's debt-to-equity ratio is 0.16.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Aarti Drugs Ltd's interest coverage ratio is 7.21.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Aarti Drugs Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Aarti Drugs Ltd's EPS is 15.96.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹427.10. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1984
Headquarters: Mumbai, Maharashtra
Core Offerings: Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, Pharmaceutical Formulations
Stock Listing: NSE (AARTIDRUGS), BSE (524348)
Promoter: Singh Family / Aarti Group
Aarti Drugs Ltd. was incorporated in 1984, commencing commercial production of pharmaceutical products in 1986. Over the decades, the company has steadily expanded its manufacturing capabilities, product portfolio, and R&D efforts. It achieved backward integration for key products, enhancing cost competitiveness. Today, Aarti Drugs is recognized as a significant manufacturer of APIs and specialty chemicals, with a strong presence in global markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceuticals (APIs, Intermediates & Formulations) | 85-90% (approx) | Operating Profit |
| Specialty Chemicals | 10-15% (approx) | Operating Profit |
Pharmaceuticals: Focuses on manufacturing a wide range of Active Pharmaceutical Ingredients (APIs) and Pharma Intermediates for diverse therapeutic categories including anti-inflammatory, anti-diabetic, anti-fungal, cardiovascular, and pain management drugs. Also produces a smaller portfolio of pharmaceutical formulations for domestic consumption.
Specialty Chemicals: Engaged in the production of various fine and specialty chemicals, leveraging its strong chemical manufacturing expertise to cater to industrial applications beyond pharmaceuticals.
Rajendra V. Singh - Chairman & Managing Director: Mr. Singh is a seasoned professional with extensive experience in the pharmaceutical industry, providing strategic direction and driving the company's growth and operational excellence.
Bonus Issue: 1:3 in August 2020.
The Aarti Drugs Ltd share price today is ₹427.10 on NSE (AARTIDRUGS), as of 26 Sept 2026.
As of 25 Sept 2026, Aarti Drugs Ltd share price is ₹427.10, with previous close ₹427.10. Today's range is ₹427.10 to ₹427.10. The 52-week range is ₹318.95 to ₹453.65.
As of today, Aarti Drugs Ltd's market cap is ₹4,215.48 crore (Small Cap).
Aarti Drugs Ltd's current P/E ratio is 23.04, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 30.
Aarti Drugs Ltd's current P/B ratio is 2.51.
Aarti Drugs Ltd's current dividend yield is N/A. Last dividend of ₹2.50 per share was declared on 19-Aug-2023.
Aarti Drugs Ltd's EPS (TTM) is ₹15.96.
Aarti Drugs Ltd. is a prominent Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, and Specialty Chemicals. It caters to a diverse range of therapeutic areas, serving both domestic and international markets with a focus on cost-effective and quality products for various ailments.
Aarti Drugs Ltd is promoted by Singh Family / Aarti Group, holding 55.03% as of 25 Sept 2026.
Aarti Drugs Ltd is listed on NSE (AARTIDRUGS) and BSE (524348). Its next quarterly results are expected on July/August 2024 (Q1 FY25).
Dividend Per Share (DPS)
